Acitretin (Ro 10-1670) is a second-generation retinoid. Acitretin is taken orally, and is typically used for psoriasis. Acitretin is a metabolite of etretinate, which was used prior to the introduction of acitretin. In contrast, acitretin's half-life is approximately 2 days. Acitretin binds to nuclear receptors that regulates gene transcription. Acitretin is readily absorbed and widely distributed after oral administration.
| Molecular Weight | 326.43 |
| Formula | C21H26O3 |
| CAS Number | 55079-83-9 |
| Form | Solid |
| Solubility (25°C) | DMSO 20 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
| Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
| Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
| Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
| Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
| Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
| Related RAR/RXR Products |
|---|
| MSU-42011
MSU-42011 is an orally active retinoid X receptor-like (RXR) agonist that potently inhibits the expression of iNOS as well as p-ERK protein levels. In addition, MSU-42011 has immunomodulatory and antitumor activities for cancer research. |
| KCL-286
KCL-286 is an orally active retinoic acid receptor-beta (RAR-beta) agonist for studies related to spinal cord injury. |
| XS-060
XS-060 is a potent anticancer agent and RXRα antagonist. |
| BPA-B9
BPA-B9 is a RXRα ligand and antagonist targeting the pRXRα-PLK1 interaction. |
| ER 50891 quarterhydrate
ER 50891 quarterhydrate is a potent antagonist of retinoic acid receptor α(RARα). |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
